Molecular pathology of epithelial ovarian neoplasias: From the phenotype-genotype correlation to new targets in diagnostics and therapy;Molekularpathologie der epithelialen ovarialneoplasien. Von der phänotyp-genotyp-korrelation zu neuen ansatzpunkten in diagnostik und therapie

Pathologe

Volumn 28, Issue 3, 2007, Pages 180-186

  Staebler, A ^a   Diebold, J ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chromosomal aberrations; Genetics; Mutations; Oncogenes; Ovarian carcinoma

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER THERAPY; CHROMOSOME ANALYSIS; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; MICROSATELLITE INSTABILITY; OVARY TUMOR; SIGNAL TRANSDUCTION; TUMOR DIAGNOSIS;

FEMALE; GENES, RAS; GENOTYPE; HUMANS; OVARIAN NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 34250207711     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-007-0910-1     Document Type: Article

References (42)

1. Abeysinghe HR, Cedrone E, Tyan T et al. (1999) Amplification of C-MYC as the origin of the homogeneous staining region in ovarian carcinoma detected by micro-FISH. Cancer Genet Cytogenet 114: 136-143
2. Anand N, Murthy S, Amann G et al. (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31: 301-305
3. Anzick SL, Kononen J, Walker RL et al. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968
4. Bjorge T, Lie AK, Hovig E et al. (2004) BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 91: 1829-1834
5. Bonome T, Lee JY, Park DC et al. (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65: 10602-10612
6. Chamorro MN, Schwartz DR, Vonica A et al. (2005) FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 24: 73-84
7. Cheng KW, Lahad JP, Kuo WL et al. (2004) The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10: 1251-1256
8. Diebold J (1998) Molekulargenetik der epithelialen Ovarialneoplasien: Korrelationen zum Phänotyp und biologischen Verhalten [Molecular genetics of epithelial ovarian neoplasms: correlations with phenotype and biological behavior]. Pathologe 19: 95-103
9. Diebold J (1999) Molecular genetics of ovarian carcinomas. Histol Histopathol 14: 269-277
10. Diebold J, Mosinger K, Peiro G et al. (2000) 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. J Pathol 190: 564-571
11. Diebold J, Suchy B, Baretton GB et al. (1996) DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis. Virchows Arch 429: 221-227
12. Gemignani ML, Schlaerth AC, Bogomolniy F et al. (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90: 378-381
13. Gilks CB, Vanderhyden BC, Zhu S et al. (2005) Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96: 684-694
14. Gras E, Catasus L, Arguelles R et al. (2001) Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92: 2829-2836
15. Hauptmann S, Denkert C, Koch I et al. (2002) Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 33: 632-641
16. Hirasawa A, Saito-Ohara F, Inoue J et al. (2003) Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9: 1995-2004
17. Hogdall EV, Christensen L, Kjaer SK et al. (2003) Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98: 66-73
18. Ichikawa Y, Nishida M, Suzuki H et al. (1994) Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54: 33-35
19. Iwabuchi H, Sakamoto M, Sakunaga H et al. (1995) Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55: 6172-6180
20. Kiechle M, Jacobsen A, Schwarz-Boeger U et al. (2001) Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 91: 534-540
21. Lassus H, Leminen A, Vayrynen A et al. (2004) ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 92: 31-39
22. Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al. (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24: 1053-1065
23. Obata K, Morland SJ, Watson RH et al. (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58: 2095-2097
24. Partheen K, Levan K, Osterberg L et al. (2004) Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer 40: 342-348
25. Rebbeck TR, Lynch HT, Neuhausen SL et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616-1622
26. Sato N, Tsunoda H, Nishida M et al. (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60: 7052-7056
27. Sato T, Saito H, Morita R et al. (1991) Allelotype of human ovarian cancer. Cancer Res 51: 5118-5122
28. Schraml P, Schwerdtfeger G, Burkhalter F et al. (2003) Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163: 985-992
29. Schwartz DR, Kardia SL, Shedden KA et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729
30. Seidman JD, Horkayne-Szakaly I, Haiba M et al. (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23: 41-44
31. Seidman JD, Russell P, Kurman RJ (2002) Surface epithelial tumors of the ovary. In: Kurman RJ (ed) Blaustein's pathology of the female genital tract, 5th edn. Springer, New York, pp 791-904
32. Shayesteh L, Lu Y, Kuo WL et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102
33. Shih I, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518
34. Singer G, Kurman RJ, Chang HW et al. (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160: 1223-1228
35. Singer G, Stohr R, Cope L et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218-224
36. Smith Sehdev AE, Sehdev PS, Kurman RJ (2003) Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol 27: 725-736
37. Staebler A, Heselmeyer-Haddad K, Bell K et al. (2002) Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 33: 47-59
38. Staebler A, Karberg B, Behm J et al. (2006) Chromosomal losses of regions on 5q and lack of high-level amplifications on 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 45: 905-917
39. Suzuki S, Moore DH, Ginzinger DG et al. (2000) An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60: 5382-5385
40. Werness BA, Ramus SJ, DiCioccio RA et al. (2004) Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 23: 29-34
41. Wu R, Zhai Y, Fearon ER et al. (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61: 8247-8255
42. Zhang L, Yang N, Huang J et al. (2005) Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res 65: 925-932